Hamatake M, Andoh T, Ishida R
Department of Pharmacy, Aichi Cancer Research Hospital, Nagoya, Japan.
Anticancer Drugs. 1997 Jul;8(6):637-42. doi: 10.1097/00001813-199707000-00013.
To investigate whether mammalian DNA topoisomerase II is directly involved in recombination events, the effects of ICRF-193, a specific catalytic inhibitor on sister chromatid exchange (SCE), were examined in MR-6 cells. ICRF-193 only slightly elevated SCE formation after 3 or 44 h treatments, while VP-16, a cleavable complex forming type of topoisomerase II inhibitor, caused significant enhancement. ICRF-193 had no effect on N-methyl-N'-nitro-N-nitrosoguanidine-induced SCE formation. It would thus appear that the inhibition of topoisomerase II does not affect recombinational repair, and that topoisomerase II inhibitors such as VP-16 and 4'-(9-acridinyl amino) methane sulfon-m-anisidide induce SCE through production of DNA strand breaks, rather than by inhibiting the enzyme activity.
为了研究哺乳动物DNA拓扑异构酶II是否直接参与重组事件,在MR-6细胞中检测了ICRF-193(一种对姐妹染色单体交换(SCE)有特异性催化抑制作用的物质)的效应。经3或44小时处理后,ICRF-193仅略微提高了SCE的形成,而VP-16(一种可形成可裂解复合物的拓扑异构酶II抑制剂)则导致显著增强。ICRF-193对N-甲基-N'-硝基-N-亚硝基胍诱导的SCE形成没有影响。因此,拓扑异构酶II的抑制似乎并不影响重组修复,并且VP-16和4'-(9-吖啶基氨基)甲磺基间茴香胺等拓扑异构酶II抑制剂是通过产生DNA链断裂来诱导SCE,而不是通过抑制酶活性。